▪ Bonesupport has raised SEK 378m (gross) through an over-subscribed directed share issue. 10.5m shares were issued at SEK 36, representing a 2.7% discount to the 10-day weighted average. The new shares are expected to become available from 29th May and will increase the total number of shares to 64.4m (a 19.5% increase). ▪ New funds will be used to scale up the company’s proven business model, with around 70% of proceeds directed into commercial activities. This principally will be supporting the launch of CERAMENT G into the important US market (with emphasis on driving clinical adoption) and in further improving sales and marketing in Europe, where the focus on commercial execution has shown good results. ▪ Investment will also be made in gaining regulatory approvals in new markets, manufacturing improvements (including in automation and increased capacity), progressing the R&D pipeline, supporting clinical studies, and for general corporate purposes. ▪ The accelerated book build was organised by Skandinaviska Enskilda Banken AB and Carnegie Investment Bank AB as Joint Bookrunners. The shares were placed with a mixture of Nordic and international institutions. The main existing shareholders, Stiftelsen Industrifonden, HealthCap V L.P. and Tellacq AB, have agreed to a 180 day lock up.
